IRVINE, California - July 27, 2006 - Masimo Corporation today
announced that it has renewed a three-year, dual source agreement with
Amerinet, a leading health care group purchasing organization with more
than 25,000 members ranging from large health systems to physician's
offices to long-term care facilities. The agreement continues coverage
of Masimo SET
® pulse oximetry technology and adds the company's breakthrough
Masimo Rainbow SET Pulse CO-Oximetry™ in standalone monitoring devices, handhelds and sensors.
"We are pleased to announce the renewal of our agreement with
Amerinet," explained Masimo Chairman and CEO Joe E. Kiani. "And we
believe that Amerinet members will be pleased to continue to have
access to superior Masimo SET pulse oximetry products as well as the
new Masimo Rainbow SET technology that will allow for the earlier
detection and treatment of an expanding number of potentially
life-threatening conditions."
Masimo SET technology allows clinicians to obtain accurate pulse
oximetry readings even in situations of motion and low-perfusion, and
has been proven more accurate and reliable in the most challenging
clinical settings by over 70 peer reviewed published clinical studies.
Building on this technology platform, Masimo has recently introduced
Masimo Rainbow SET, world's first device capable of noninvasively
measuring carboxyhemoglobin, methemoglobin and oxyhemoglobin saturation
levels in the blood
In clinical studies and in the field, Masimo Rainbow SET is already
proving itself effective in detecting carbon monoxide poisoning in
seconds, allowing accurate diagnosis and early treatment of a
life-threatening problem that is frequently misdiagnosed as flu or
migraine. In addition, a recent Johns Hopkins study found that
methemoglobinemia, a potentially lethal condition that starves the
tissues of oxygen, is much more common in hospitalized patients than
previously realized.
About Amerinet
Amerinet is one of the most
innovative and effective health care group purchasing organizations in
the United States, partnering with members to improve their operating
margins. More than 2,100 hospitals and 35,000 non-acute care facilities
create new revenue and reduce expenses with Amerinet's tools for group
purchasing, supply chain management, clinical consulting, revenue cycle
management, and information and education.
About
Masimo
Masimo
develops innovative monitoring technologies that significantly improve
patient care-helping solve "unsolvable" problems. In 1995, the company
debuted Read-Through Motion and Low Perfusion pulse oximetry, known as
SET, and with it virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. Over 100 clinical
studies have confirmed that Masimo SET technology allows clinicians to
accurately monitor blood oxygen saturation in critical care situations.
In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry,
which, for the first time, noninvasively monitors the level of carbon
monoxide and methemoglobin in the blood, allowing early detection and
treatment of potentially life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient
Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to
New Sites and Applications." Additional information about Masimo and
its products may be found at www.masimo.com
Masimo, SET, Signal Extraction Technology and
Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to
New Sites and Applications are registered trademarks of Masimo Corp.
Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.
Contact: Tom McCall
Vice President, Corporate Communications
949-790-7075
tmccall@masimo.com